AVPR2 and autosomal dominant polycystic kidney disease: Recently, prospective studies in adult patients at risk for rapid ADPKD progression have demonstrated that vasopressin V2 receptor antagonism, which directly targets pathways implicated in ADPKD cystogenesis, significantly slows TKV increase and estimated glomerular filtration rate (eGFR) decline6–9.